NRX Pharmaceuticals, Inc. (NRXP) stock
NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.45+0.30 (+13.95%)
Close on Nov 17, 2026Market cap $106.08MP/E –Yield –
Earnings
NRX Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q3 FY2023
–
EPS, Q3 FY2023
-$0.07
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of NRX Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | Aug 17, 2026before the open | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 18, 2025after the close | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 21, 2025after the close | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 21, 2025after the close | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 15, 2024after the close | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 15, 2024after the close | – | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 16, 2024after the close | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Apr 2, 2024before the open | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023before the open | – | – | -$0.07 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 31, 2023before the open | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022before the open | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
NRX Pharmaceuticals has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When NRX Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases NRX Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Update
- Results
- News
- News
- News
- News
- Update
- Update
- Update
- Update
- News
- Update
- News
See a number that looks wrong?